Statement on Glucagen Hypokit supply 2 August 2023 Novo Nordisk has notified the Therapeutic Goods Administration that the Glucagen Hypokit is currently in a shortage that will last until 30 September 2023. The Glucagen Hypokit is used to treat severe hypoglycaemia where a person is unconscious or unable to take oral hypo treatments. If a person has a severe hypo and you don’t have a Hypokit you need to call 000 immediately. Diabetes Australia is working with the diabetes sector and the TGA to ensure people at highest risk are prioritized access to available supply. The TGA have also activated Section 19A provisions and is arranging imports of Hypokits from other countries. If you have concerns please talk to someone from your diabetes healthcare team.
News 16 January 2026 Wegovy to be listed on PBS The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended Wegovy (semaglutide) be subsidised through the Pharmaceutical Benefits Scheme (PBS) for adults with established cardiovascular disease and obesity. Diabetes Australia’s Group CEO... Continue Reading
News 18 December 2025 A merry, bright and healthy festive season for Australians living with diabetes As Australians prepare for a festive season filled with food, family and good wishes, people living with diabetes are being... Continue Reading
Blog 17 December 2025 A realistic approach to type 2 diabetes remission Remission may be achievable for some. For others, stable and consistent management is the most realistic and sustainable path. If your HbA1c moves from 8.5% to 7.5%, you're making a real difference in your long-term health. Continue Reading
